Company Overview and News
Please be advised that certain statements on this call constitute forward-looking information. These statements relate to future events or our expectations for future performance. All statements, other than those of historical facts, may be forward-looking and we caution the listener.
CALGARY, Alberta, May 09, 2018 (GLOBE NEWSWIRE) -- Freehold Royalties Ltd. (Freehold) (TSX:FRU) announced today that all nominees listed in its notice of meeting and information circular dated March 23, 2018, were elected as directors of Freehold at its Annual Meeting of Shareholders held today in Calgary.
CALGARY, Alberta, May 09, 2018 (GLOBE NEWSWIRE) -- Freehold Royalties Ltd. (Freehold) (TSX:FRU) announced first quarter results for the period ended March 31, 2018.
CALGARY, Alberta, April 11, 2018 (GLOBE NEWSWIRE) -- Freehold Royalties Ltd. (Freehold) (TSX:FRU) announces that its Board of Directors has declared a dividend of Cdn. $0.0525 per common share to be paid on May 15, 2018 to shareholders of record on April 30, 2018.
CALGARY, Alberta, April 09, 2018 (GLOBE NEWSWIRE) -- Freehold Royalties Ltd. (Freehold) (TSX:FRU) announces it will hold its Investor Day in Toronto today beginning at 3:00pm EST. The event will include a formal presentation by Freehold's management and technical teams, showcasing Freehold's 2017 Asset Book.
The following slide deck was published by Freehold Royalties Ltd in conjunction with their 2017 Q4 earnings call.
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
A rally in oil prices that started late last year and shows no signs of stopping in 2018 is expected to pave the way for bigger payouts for long-suffering Canadian energy investors as fourth-quarter reporting season gets underway in the next month.
The big economic events that just took place were the passage of the Trump tax cut, the rate hike of 0.25% by the Fed with projections to make three more next year, and the ramping up of balance sheet reduction at the Fed. All will have either a dramatic new impact or will add dramatically to prior actions. On the one hand, we have added liquidity into our economy, and on the other hand we have reduced liquidity.
* Freehold Royalties Ltd says increasing 2017 average production range to 12.0-12.5 mboe/d Source text for Eikon: Further company coverage:
32 of 80 Monthly Paying (MoPay) Canadian (CDN) Equities were tagged "safer" because they showed positive annual-returns, and free cash-flow yield greater than their dividend yield per 10/3/17 market data.
Precision Drilling Corporation ("Precision") (TSX:PD)(NYSE:PDS) announced today the addition of Susan M. MacKenzie to its board of directors.
Good morning, ladies and gentlemen. Welcome to the Freehold Royalties Limited Second Quarter Conference Call. Please be advised that certain statements on this call constitute forward-looking statements. These statements relate to future events or our expectations for future performance. All statements other than statements of historical facts may be forward-looking, and we caution the listener that actual results may vary from estimates.
35 of 90 Top Monthly Paying (MoPay) Canadian (CDN) Equities showed positive annual-returns, and free cash-flow yields greater than dividend yields 6/30/17. Those 35 were tagged "safer".
16h - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
17h - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...